Practice
New oral anticoagulants
Dongmei Sun and Alejandro Lazo-Langner
CMAJ March 05, 2013 185 (4) E212; DOI: https://doi.org/10.1503/cmaj.120078
Dongmei Sun
From the Departments of Medicine (Sun, Lazo-Langner) and Epidemiology and Biostatistics (Lazo-Langner), University of Western Ontario, London, Ont.
MD MScAlejandro Lazo-Langner
From the Departments of Medicine (Sun, Lazo-Langner) and Epidemiology and Biostatistics (Lazo-Langner), University of Western Ontario, London, Ont.
MD MSc![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
New oral anticoagulants
Dongmei Sun, Alejandro Lazo-Langner
CMAJ Mar 2013, 185 (4) E212; DOI: 10.1503/cmaj.120078
Jump to section
- Article
- Dabigatran etexilate and rivaroxaban are approved in Canada for several indications
- Both drugs require dose adjustment in people with renal impairment and are contraindicated in those with liver disease
- Normal results of common coagulation tests do not exclude clinically relevant anticoagulation
- Other adverse effects and drug interactions may limit their effectiveness
- There is no clinically proven agent that can reverse anticoagulation with either drug
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.